Servier drug Tibsovo is now approved for treating advanced cases of myelodysplastic syndrome that have an IDH1 mutation. It’s the first approval of a targeted therapy for this type of cancer.
HealthBook+ provides a way for individuals to aggregate and use their personal health information safely and securely to power AI engines that direct people to their next best health action. Importantly, it also gives employers predictive insights to help them provide the most relevant benefits for their employees.
The healthcare industry must prioritize the development and implementation of universal tools that can efficiently navigate, interpret, and derive value from the growing wealth of health data.
In the runup to the MedCity INVEST Digital Health conference, Christoph Besmer, a trade commissioner and head of investment promotion with Swiss Business Hub USA, talked about the “X Marks the Spot” campaign and how Switzerland Global Enterprise hopes to strengthen ties with U.S. health tech companies.